首页> 外文期刊>International journal of applied mechanics >Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy
【24h】

Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy

机译:淋巴结对原发性肿瘤标准化摄取性摄取价值的预后价值,具有明确的化学疗法治疗食管鳞状细胞癌

获取原文
获取原文并翻译 | 示例
           

摘要

We aimed to investigate the prognostic value of the relative maximum standardized uptake value (SUV) of metastatic lymph node (LN) compared with that of primary tumor (SUVLN/SUVTumor) based on a pretreatment [F-18]-FDG PET /CT scan in patients with clinically node-positive esophageal squamous cell carcinoma (cN+ ESCC) treated with definitive chemoradiotherapy (dCRT). We retrospectively evaluated cN+ ESCC patients who underwent a PET/CT scan before dCRT. Time-dependent receiver operating characteristics analysis was performed to identify the optimal cutoff value for SUVLN/SUVTumor. Prognostic influences of SUVLN/SUVTumor on distant metastasis-free survival (DMFS) and overall survival (OS) were evaluated using the Kaplan-Meier method and log-rank test for univariate analysis and Cox's proportional hazards regression model for multivariate analysis. We identified 112 patients with newly diagnosed cN+ ESCC. After a median follow-up of 32.0 months, 50 (44.6%) patients had distant failure and 84 (75.0%) patients died. Patients with high SUVLN/SUVTumor (>= 0.39) experienced worse outcomes than low SUVLN/SUVTumor (< 0.39) (two-year DMFS: 26% vs. 70%, p < 0.001; two-year OS: 21% vs. 48%, p = 0.001). Multivariate analysis showed that SUVLN/SUVTumor was an independent prognostic factor for both DMFS (adjusted HR 2.24, 95% CI 1.34-3.75, p = 0.002) and OS (adjusted HR 1.61, 95% CI 1.03-2.53, p = 0.037). Pretreatment of SUVLN/SUVTumor is a simple and useful marker for prognosticating DMFS and OS in cN+ ESCC patients treated with dCRT, which may help in tailoring treatment and designing future clinical trials.
机译:我们的旨在研究基于预处理的原发性肿瘤(SUVLN / SUVTUMOR)与原发性肿瘤(SUVLN / SUVTumor)相对最大标准化摄取值(SUV)的预后值[F-18] -FDG PET / CT扫描在临床上阳性食管鳞状细胞癌(CN + ESCC)的患者中,用明确的化学疗法(DCRT)处理。我们回顾性地评估了在DCRT之前接受了PET / CT扫描的CN + ESCC患者。执行时间依赖的接收器操作特性分析以确定SUVLN / SUVTumor的最佳截止值。使用Kaplan-Meier方法和单变量分析和Cox比例危害回归模型,评估Suvln / Suvtumor对远处转移存活(DMFS)和总存活(OS)的预后对远处转移存活(DMF)和总存活(OS)进行多元分析的回归模型。我们确定了112名新诊断的CN + ESCC患者。在32.0个月的中位随访后,50名(44.6%)患者的患者近距离发生,84例(75.0%)患者死亡。高SUVLN / SUVTUMOR(> = 0.39)的患者经历了比低SUVLN / SUVTUMOR(<0.39)的更差的结果(两年DMFS:26%vs. 70%,P <0.001;两年的OS:21%与48 %,p = 0.001)。多变量分析表明,Suvln / Suvtumor是DMFS的独立预后因子(调节的HR 2.24,95%CI 1.34-3.75,P = 0.002)和OS(调节的HR 1.61,95%CI 1.03-2.53,P = 0.037)。 Suvln / Suvtumor的预处理是一种简单而有用的标记,用于预后的DMFS和随着DCRT治疗的CN + ESCC患者中的OS,这可能有助于定制治疗和设计未来的临床试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号